Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL8027991 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL2763245 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL56857 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL1801721 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL1136528 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL27672961 | 0.98 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL29250210 | 0.97 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL22769647 | 0.94 | SLC7A5 (0.39) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL20678156 | 0.94 | SLC7A5 (0.39) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3967555 | 0.94 | SLC7A5 (0.39) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834636-A1 | APPARATUS AND METHOD FOR MOLECULAR SEPARATION, PURIFICATION, AND SENSING | Lux Bio Group, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| WO-2013151532-A1 | APPARATUS AND METHOD FOR MOLECULAR SEPARATION, PURIFICATION, AND SENSING | LUX BIO GROUP, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| US-20130256144-A1 | APPARATUS AND METHOD FOR MOLECULAR SEPARATION, PURIFICATION, AND SENSING | LUX BIO GROUP, INC. (US) | 2013-10-03 | — | — | US | claimed |
| US-20240238369-A1 | Conformationally Specific Viral Immunogens | CALDER BIOSCIENCES INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11993633-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240168012-A1 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | JUNO THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024084096-A1 | PHOTOSENSITIVE DIAZIRINE-CONJUGATED PHOSPHOLIPIDS AND USES THEREOF | Universite de Bordeaux (FR) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356930-A1 | PHOTOSENSITIVE DIAZIRINE-CONJUGATED PHOSPHOLIPIDS AND USES THEREOF | UNIVERSITE DE BORDEAUX (FR) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023230548-A1 | METHOD FOR PREDICTING RESPONSE TO A T CELL THERAPY | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-11752191-B2 | Conformationally-specific viral immunogens | CALDER BIOSCIENCES INC (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230178239-A1 | METHODS OF IDENTIFYING FEATURES ASSOCIATED WITH CLINICAL RESPONSE AND USES THEREOF | JUNO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| WO-1993018152-A1 | MN GENE AND PROTEIN | CIBA CORNING DIAGNOSTICS CORP. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-5243030-A | Containing a polypeptide corresponding to a specific region of virus matrix protein; diagnosis/medical | SRI INTERNATIONAL (US) | 1993-09-07 | — | — | US | disclosed |
| US-5169836-A | Polypeptides with protected or unprotected terminal amino and carboxy group; anticoagulants | TRUSTEES OF THE UNIVERSITY OF PENNA. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5136019-A | Corresponding to specific region of type A influenza virus matrix protein | SRI INTERNATIONAL (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1991004041-A1 | PROCESS FOR INDUCING ANALGESIA, PEPTIDES AND THERAPEUTIC COMPOSITIONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1991-04-04 | — | — | WO | disclosed |
| US-4981782-A | Synthetic peptides for diagnosis and prevention of influenza virus infection and their use | SRI INTERNATIONAL (US) | 1991-01-01 | — | — | US | disclosed |
| US-4859765-A | HORMONES, RESIN PEPTIDES, IMMUNOLOGY, DIAGNOSIS | SYNTEX (U.S.A.) INC. (US) | 1989-08-22 | — | — | US | disclosed |
| WO-1985003724-A1 | IMPROVEMENTS IN OR RELATING TO THE PRODUCTION OF MALARIA VACCINES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-08-29 | — | — | WO | disclosed |
| US-4493795-A | ANTIGENS, VIRICIDES, DIAGNOSTIC REAGENTS | SYNTEX (U.S.A.) INC. (US) | 1985-01-15 | — | — | US | disclosed |